Alzheimer's drug shows potential in slowing disease

There is new hope in the fight against Alzheimer's Disease but it comes with a dose of caution.
Results of a phase three clinical trial show an experiental drug does seem to slow cognitive decline in early onset patients, but of course, there are concerns about safety issues.

Lacanemab is a monoclonal antibody drug, targeting abnormal clumps of beta-amyloid plaque on the brain. A sticky protein contributing to cognitive decline.

All trial participants had early-stage Alzheimer's Disease. Preliminary results show lecanemab slowed cognitive and functional decline by 27 percent. However, the trial also uncovered some safety concerns.

The concerns included reactions to IV infusion, brain swelling and brain bleeding.

READ MORE: https://www.wkyc.com/article/news/health/experimental-alzheimers-drug-shows-promise/95-ac97135e-36f6-4cbf-a8aa-c8b0f3258c99

At 3News, we’re not here to tell you the news, we’re here to share the stories that you say matter most to you. Share your ideas, thoughts, concerns and engage in conversations about the communities in which we all call home.

Follow 3News on Social:

Facebook: https://www.facebook.com/wkyc.channel3/
Twitter: https://twitter.com/wkyc
Instagram: https://www.instagram.com/wkyc3/

Visit our site: https://www.wkyc.com/
And be sure to download our app here: https://wkyc.com/app
Be the first to comment